{"id":47426,"date":"2022-08-18T12:02:12","date_gmt":"2022-08-18T10:02:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/"},"modified":"2022-08-18T12:02:12","modified_gmt":"2022-08-18T10:02:12","slug":"axonics-to-participate-in-september-investor-conferences","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/","title":{"rendered":"Axonics\u00ae to Participate in September Investor Conferences"},"content":{"rendered":"
\n

IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management is scheduled to present at the following investor conferences:\n<\/p>\n

<\/a><\/p>\n

\nEvent: Wells Fargo Healthcare Conference
\n
Date: Thursday, September 8, 2022
\n
Time: 10:25 a.m. Eastern Time\n<\/p>\n

\nEvent: Morgan Stanley Healthcare Conference
\n
Date: Monday, September 12, 2022
\n
Time: 11:05 a.m. Eastern Time\n<\/p>\n

\nInterested parties may access a live and archived webcast of each presentation by visiting the Axonics investor relations website<\/a>.\n<\/p>\n

\nAbout Axonics<\/b>\n<\/p>\n

\nBased in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte<\/a> Technology Fast 500\u2122 and the 2022 Financial Times<\/a> ranking of the 500 fastest growing companies in the Americas.\n<\/p>\n

\nAxonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and\/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company\u2019s best-in-class urethral bulking hydrogel, Bulkamid\u00ae<\/sup>, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics\u2019 clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nNeil Bhalodkar
\n
949-336-5293
\n
ir@axonics.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management is scheduled to present at the following investor conferences: Event: Wells Fargo Healthcare Conference Date: Thursday, September 8, 2022 Time: 10:25 a.m. Eastern Time … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47426","6":"format-standard","7":"category-industry"},"yoast_head":"\nAxonics\u00ae to Participate in September Investor Conferences - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Axonics\u00ae to Participate in September Investor Conferences - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management is scheduled to present at the following investor conferences: Event: Wells Fargo Healthcare Conference Date: Thursday, September 8, 2022 Time: 10:25 a.m. Eastern Time ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-18T10:02:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220818005007\/en\/788134\/21\/Axonics_Logo_-_Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-to-participate-in-september-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-to-participate-in-september-investor-conferences\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Axonics\u00ae to Participate in September Investor Conferences\",\"datePublished\":\"2022-08-18T10:02:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-to-participate-in-september-investor-conferences\\\/\"},\"wordCount\":276,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220818005007\\\/en\\\/788134\\\/21\\\/Axonics_Logo_-_Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-to-participate-in-september-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-to-participate-in-september-investor-conferences\\\/\",\"name\":\"Axonics\u00ae to Participate in September Investor Conferences - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220818005007\\\/en\\\/788134\\\/21\\\/Axonics_Logo_-_Color.jpg\",\"datePublished\":\"2022-08-18T10:02:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-to-participate-in-september-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-to-participate-in-september-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-to-participate-in-september-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220818005007\\\/en\\\/788134\\\/21\\\/Axonics_Logo_-_Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220818005007\\\/en\\\/788134\\\/21\\\/Axonics_Logo_-_Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/axonics-to-participate-in-september-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Axonics\u00ae to Participate in September Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Axonics\u00ae to Participate in September Investor Conferences - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Axonics\u00ae to Participate in September Investor Conferences - Pharma Trend","og_description":"IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management is scheduled to present at the following investor conferences: Event: Wells Fargo Healthcare Conference Date: Thursday, September 8, 2022 Time: 10:25 a.m. Eastern Time ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-18T10:02:12+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220818005007\/en\/788134\/21\/Axonics_Logo_-_Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Axonics\u00ae to Participate in September Investor Conferences","datePublished":"2022-08-18T10:02:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/"},"wordCount":276,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220818005007\/en\/788134\/21\/Axonics_Logo_-_Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/","url":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/","name":"Axonics\u00ae to Participate in September Investor Conferences - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220818005007\/en\/788134\/21\/Axonics_Logo_-_Color.jpg","datePublished":"2022-08-18T10:02:12+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220818005007\/en\/788134\/21\/Axonics_Logo_-_Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220818005007\/en\/788134\/21\/Axonics_Logo_-_Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/axonics-to-participate-in-september-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Axonics\u00ae to Participate in September Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47426"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47426\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}